1866 THE EFFICIENCY OF SECOND-LINE CHEMOTHERAPY WITH GEMCITABINE AND PACLITAXEL FOR ADVANCED UROTHELIAL CARCINOMA RESISTANT TO CISPLATIN-BASED CHEMOTHERAPY

Abstract

You have accessJournal of UrologyBladder Cancer: Metastatic Disease + Staging1 Apr 20131866 THE EFFICIENCY OF SECOND-LINE CHEMOTHERAPY WITH GEMCITABINE AND PACLITAXEL FOR ADVANCED UROTHELIAL CARCINOMA RESISTANT TO CISPLATIN-BASED CHEMOTHERAPY Chikako Nishihara, Katsuyuki Kuratsukuri, Taro Iguchi, Satoshi Tamada, Tomoaki Tanaka, Junji Uchida, Hidenori Kawashima, and Tatsuya Nakatani Chikako NishiharaChikako Nishihara Osaka, Japan More articles by this author , Katsuyuki KuratsukuriKatsuyuki Kuratsukuri Osaka, Japan More articles by this author , Taro IguchiTaro Iguchi Osaka, Japan More articles by this author , Satoshi TamadaSatoshi Tamada Osaka, Japan More articles by this author , Tomoaki TanakaTomoaki Tanaka Osaka, Japan More articles by this author , Junji UchidaJunji Uchida Osaka, Japan More articles by this author , Hidenori KawashimaHidenori Kawashima Osaka, Japan More articles by this author , and Tatsuya NakataniTatsuya Nakatani Osaka, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.2285AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The objective of this study is to evaluate the efficacy and toxicity of combination chemotherapy with gemcitabine and paclitaxel as a second-line regimen for patients with advanced or metastatic urothelial carcinoma (UC) after the failure of cisplatin-based chemotherapy. METHODS This study was approved by the Institutional Review Board of Osaka City University and 31 patients with UC after the failure of cisplatin-based chemotherapy were enrolled in this study between from January 2002 to August 2012. Patients administrated paclitaxel (200 mg/m2; day 1) and gemcitabine (1000 mg/m2; day 1, 8, 15) and repeated every 4 weeks. Some ‘unfit' patients who were elderly or low activities after first-line chemotherapy received docetaxel (70 mg/m2) instead of paclitaxel. Patients were evaluated after every 1 cycle of the therapy by radiological imaging. RESULTS The patients received 1-4 cycles of gemcitabine/paclitaxel or gemcitabibe/docetaxel treatment (a median: 2 cycles). Overall response rate was 29% including two patients who had complete response, and disease control rate was 58%. Median overall survival was 14 months, and median progression-free survival was 4 months. Compared with paclitaxel and docetaxel, overall survival and progression-free survival were not significantly different. In patients who received gemcitabine/cisplatin as first-line chemotherapy, the overall response rate of gemcitabine/paclitaxel and gemcitabine/docetaxel were 40% and 12.5% respectively. In adverse effect, grade 3/4 neutropenia in 20 patients (65%), grade 3/4 thrombopenia in 8 patients (26%), grade 3 anemia in 3 patients (10%) were observed, but there were no severe infections and no transfusion. CONCLUSIONS The combination chemotherapy with gemcitabine and paclitaxel are favorable and tolerable regimen as a second-line treatment for patients with UC after the failure of cisplatin-based chemotherapy and docetaxel can be substitutable for paclitaxel in this regimen. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e765 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information Chikako Nishihara Osaka, Japan More articles by this author Katsuyuki Kuratsukuri Osaka, Japan More articles by this author Taro Iguchi Osaka, Japan More articles by this author Satoshi Tamada Osaka, Japan More articles by this author Tomoaki Tanaka Osaka, Japan More articles by this author Junji Uchida Osaka, Japan More articles by this author Hidenori Kawashima Osaka, Japan More articles by this author Tatsuya Nakatani Osaka, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...